Page last updated: 2024-11-12
recoflavone
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Cross-References
ID Source | ID |
---|---|
PubMed CID | 9952125 |
CHEMBL ID | 4297606 |
SCHEMBL ID | 2483541 |
MeSH ID | M0336723 |
Synonyms (26)
Synonym |
---|
recoflavone [inn] |
recoflavone |
u96j5lg435 , |
203191-10-0 |
da 6034 |
unii-u96j5lg435 |
acetic acid, ((2-(3,4-dimethoxyphenyl)-5-methoxy-4-oxo-4h-1-benzopyran-7-yl)oxy)- |
7-(carboxymethyloxy)-3',4',5-trimethoxyflavone |
da-6034 |
7-carboxymethoxyloxy-3',4',5-trimethoxyflavone |
acetic acid, 2-((2-(3,4-dimethoxyphenyl)-5-methoxy-4-oxo-4h-1-benzopyran-7-yl)oxy)- |
((2-(3,4-dimethoxyphenyl)-5-methoxy-4-oxo-4h-chromen-7-yl)oxy)acetic acid |
SCHEMBL2483541 |
DTXSID50174205 |
2-[2-(3,4-dimethoxyphenyl)-5-methoxy-4-oxochromen-7-yl]oxyacetic acid |
da-60342 |
DB12058 |
2-((2-(3,4-dimethoxyphenyl)-5-methoxy-4-oxo-4h-chromen-7-yl)oxy)acetic acid |
acetic acid, 2-[[2-(3,4-dimethoxyphenyl)-5-methoxy-4-oxo-4h-1-benzopyran-7-yl]oxy]- |
SB18971 |
da6034 |
Q27290945 |
CHEMBL4297606 |
HY-106449 |
CS-0025847 |
AKOS040753717 |
Research Excerpts
Toxicity
Excerpt | Reference | Relevance |
---|---|---|
" Twenty-two mild adverse events were reported in 14 subjects." | ( Pharmacokinetics, safety and tolerability of DA-6034, an anti-inflammatory agent, after single and multiple oral administrations in healthy volunteers. Chung, JY; Jang, IJ; Kim, JR; Lee, J; Lim, KS; Shin, KH, 2014) | 0.4 |
Pharmacokinetics
Dosage Studied
Excerpt | Relevance | Reference |
---|---|---|
" For both the single- and multiple-dose administrations, the coefficients of variation of the area under the plasma concentration-time curve to the last observation (AUClast) and the area under the plasma concentration-time curve over the dosing interval at steady state (AUCss,τ) ranged from 16." | ( Pharmacokinetics, safety and tolerability of DA-6034, an anti-inflammatory agent, after single and multiple oral administrations in healthy volunteers. Chung, JY; Jang, IJ; Kim, JR; Lee, J; Lim, KS; Shin, KH, 2014) | 0.4 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (16)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (6.25) | 18.2507 |
2000's | 9 (56.25) | 29.6817 |
2010's | 6 (37.50) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 23.02
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (23.02) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 1 (5.88%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 16 (94.12%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |